Assessment of vascular effects of tamoxifen and its metabolites on the rat perfused hindquarter vascular bed

Basic and Clinical Pharmacology and Toxicology

Volumn 104, Issue 5, 2009, Pages 400-407

  Montenegro, Marcelo F ^a   Pessa, Lisandra R ^a   Gomes, Valéria A ^b   Desta, Zeruesenay ^c   Flockhart, David A ^c   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ACETYLCHOLINE; DRUG METABOLITE; ENDOXIFEN; LIPID PEROXIDE; NITRIC OXIDE; NITRITE; NORTAMOXIFEN; TAMOXIFEN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FLUOROMETRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RESISTANCE BLOOD VESSEL; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; HEART RATE; MALE; NITRIC OXIDE; OXIDATIVE STRESS; PERFUSION; RATS; RATS, WISTAR; TAMOXIFEN; THIOBARBITURIC ACID REACTIVE SUBSTANCES; VASCULAR RESISTANCE;

RATTUS;

EID: 64549106977     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00377.x     Document Type: Article

References (47)

1. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996 14 : 429 33.
2. de Medina P, Payre BL, Bernad J, Bosser I, Pipy B, Silvente-Poirot S et al. Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. J Pharmacol Exp Ther 2004 308 : 1165 73.
3. Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD et al. Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 2001 21 : 255 61.
4. Grainger DJ, Metcalfe JC. Tamoxifen: teaching an old drug new tricks? Nat Med 1996 2 : 381 5.
5. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998 45 : 608 12.
6. Figtree GA, Webb CM, Collins P. Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. J Pharmacol Exp Ther 2000 295 : 519 23.
7. Hutchison SJ, Chou TM, Chatterjee K, Sudhir K. Tamoxifen is an acute, estrogen-like, coronary vasodilator of porcine coronary arteries in vitro. J Cardiovasc Pharmacol 2001 38 : 657 65.
8. Leung HS, Yung LM, Leung FP, Yao X, Chen ZY, Ko WH et al. Tamoxifen dilates porcine coronary arteries: roles for nitric oxide and ouabain-sensitive mechanisms. Br J Pharmacol 2006 149 : 703 11.
9. Stamatelopoulos KS, Lekakis JP, Poulakaki NA, Papamichael CM, Venetsanou K, Aznaouridis K et al. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. Am Heart J 2004 147 : 1093 9.
10. Clarke SC, Schofield PM, Grace AA, Metcalfe JC, Kirschenlohr HL. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation 2001 103 : 1497 502.
11. Vitseva O, Flockhart DA, Jin Y, Varghese S, Freedman JE. The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates. J Pharmacol Exp Ther 2005 312 : 1144 50.
12. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 2002 30 : 869 74.
13. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991 51 : 4837 44.
14. Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982 42 : 317 23.
15. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004 310 : 1062 75.
16. Lim YC, Li L, Desta Z, Zhao Q, Rae JM, Flockhart DA et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 2006 318 : 503 12.
17. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004 85 : 151 9.
18. Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N- desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005 55 : 471 8.
19. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003 95 : 1758 64.
20. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005 23 : 9312 8.
21. Mandlekar S, Hebbar V, Christov K, Kong AN. Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. Cancer Res 2000 60 : 6601 6.
22. Ek RO, Yildiz Y, Cecen S, Yenisey C, Kavak T. Effects of tamoxifen on myocardial ischemia-reperfusion injury model in ovariectomized rats. Mol Cell Biochem 2008 308 : 227 35.
23. + channels in endothelium-dependent and nitric oxide-mediated dilatation of the rat hindquarters vasculature. Clin Exp Pharmacol Physiol 2004 31 : 254 60.
24. Tracey WR, Tse J, Carter G. Lipopolysaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors. J Pharmacol Exp Ther 1995 272 : 1011 5.
25. Dias-Junior CA, Gladwin MT, Tanus-Santos JE. Low-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboembolism. Free Radic Biol Med 2006 41 : 1764 70.
26. Cau SB, Dias-Junior CA, Montenegro MF, de Nucci G, Antunes E, Tanus-Santos JE. Dose-dependent beneficial hemodynamic effects of BAY 41-2272 in a canine model of acute pulmonary thromboembolism. Eur J Pharmacol 2008 581 : 132 7.
27. Dias-Junior CA, Montenegro MF, Florencio BC, Tanus-Santos JE. Sildenafil improves the beneficial haemodynamic effects of intravenous nitrite infusion during acute pulmonary embolism. Basic Clin Pharmacol Toxicol 2008 103 : 374 9.
28. Goldhaber SZ. Tamoxifen: preventing breast cancer and placing the risk of deep vein thrombosis in perspective. Circulation 2005 111 : 539 41.
29. Grainger DJ, Schofield PM. Tamoxifen for the prevention of myocardial infarction in humans: preclinical and early clinical evidence. Circulation 2005 112 : 3018 24.
30. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000 87 : 840 4.
31. El-Beshbishy HA. Hepatoprotective effect of green tea (Camellia sinensis) extract against tamoxifen-induced liver injury in rats. J Biochem Mol Biol 2005 38 : 563 70.
32. Nazarewicz RR, Zenebe WJ, Parihar A, Larson SK, Alidema E, Choi J et al. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res 2007 67 : 1282 90.
33. Wakatsuki A, Ogawa Y, Saibara T, Okatani Y, Fukaya T. Size and oxidative susceptibility of low-density lipoprotein particles in breast cancer patients with tamoxifen-induced fatty liver. J Clin Endocrinol Metab 2002 87 : 3676 81.
34. Wiseman H. Tamoxifen as an antioxidant and cardioprotectant. Biochem Soc Symp 1995 61 : 209 19.
35. Wiseman H, Laughton MJ, Arnstein HR, Cannon M, Halliwell B. The antioxidant action of tamoxifen and its metabolites. Inhibition of lipid peroxidation. FEBS Lett 1990 263 : 192 4.
36. Schulz E, Jansen T, Wenzel P, Daiber A, Munzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008 10 : 1115 26.
37. Kleinbongard P, Dejam A, Lauer T, Rassaf T, Schindler A, Picker O et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 2003 35 : 790 6.
38. Metzger IF, Sertorio JT, Tanus-Santos JE. Relationship between systemic nitric oxide metabolites and cyclic GMP in healthy male volunteers. Acta Physiol 2006 188 : 123 7.
39. Metzger IF, Sertorio JT, Tanus-Santos JE. Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. Free Radic Biol Med 2007 43 : 987 92.
40. Demacq C, Metzger IF, Gerlach RF, Tanus-Santos JE. Inverse relationship between markers of nitric oxide formation and plasma matrix metalloproteinase-9 levels in healthy volunteers. Clin Chim Acta 2008 394 : 72 6.
41. Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P et al. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med 2006 40 : 295 302.
42. Castro MM, Rizzi E, Rascado RR, Nagassaki S, Bendhack LM, Tanus-Santos JE. Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur J Pharmacol 2004 498 : 189 94.
43. Nagassaki S, Sertorio JT, Metzger IF, Bem AF, Rocha JB, Tanus-Santos JE. eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic Biol Med 2006 41 : 1044 9.
44. Souza-Costa DC, Figueiredo-Lopes L, Alves-Filho JC, Semprini MC, Gerlach RF, Cunha FQ et al. Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Crit Care Med 2007 35 : 239 45.
45. Mark CJ, Tatchum-Talom R, Martin DS, Eyster KM. Effects of estrogens and selective estrogen receptor modulators on vascular reactivity in the perfused mesenteric vascular bed. Am J Physiol Regul Integr Comp Physiol 2007 293 : R1969 75.
46. Wallen WJ, Belanger MP, Wittnich C. Sex hormones and the selective estrogen receptor modulator tamoxifen modulate weekly body weights and food intakes in adolescent and adult rats. J Nutr 2001 131 : 2351 7.
47. Pham-Dang ML, Clement R, Mercier I, Calderone A. Comparative effects of tamoxifen and angiotensin II Type-1 receptor antagonist therapy on the hemodynamic profile of the ovariectomized female rat. Can J Physiol Pharmacol 2003 81 : 915 9.